

Supplementary Material

Cell line	5-FU treatment	SubG1 population
HCT116 Chk2(-)	-	3.5%
	+	25.5%
BP resistant HCT116 Chk2(-)	-	4.6%
	+	40.6%
HCT116 Bax(-)	-	5.5%
	+	20.8%
BP resistant HCT116 Bax(-)	-	18.9%
	+	36.8%
HCT116 p53(-)	-	7.8%
	+	9.8%
BP resistant HCT116 Bax(-)	-	24.9%
	+	36.7%
HCT116 Puma(-)	-	5.6%
	+	19.0%
BP resistant HCT116 Puma(-)	-	6.4%
	+	41.2%

Supplementary Table 1. Comparison of SubG1 fraction of HCT116 variants and their BP resistant clones. HCT116 Chk2(-), Bax(-), p53(-), Puma(-) and their BP resistant clones were treated with 5-FU, as indicated in Figure 5. Cell cycle profile was determined by PI staining. SubG1 fraction is indicated.